150 related articles for article (PubMed ID: 37280643)
21. Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis.
Furin JJ; Du Bois J; van Brakel E; Chheng P; Venter A; Peloquin CA; Alsultan A; Thiel BA; Debanne SM; Boom WH; Diacon AH; Johnson JL
Antimicrob Agents Chemother; 2016 Nov; 60(11):6591-6599. PubMed ID: 27550361
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
von Groote-Bidlingmaier F; Patientia R; Sanchez E; Balanag V; Ticona E; Segura P; Cadena E; Yu C; Cirule A; Lizarbe V; Davidaviciene E; Domente L; Variava E; Caoili J; Danilovits M; Bielskiene V; Staples S; Hittel N; Petersen C; Wells C; Hafkin J; Geiter LJ; Gupta R
Lancet Respir Med; 2019 Mar; 7(3):249-259. PubMed ID: 30630778
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F; Diacon AH; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Egizi E; Moreira J; Timm J; McHugh TD; Wills GH; Bateson A; Hunt R; Van Niekerk C; Li M; Olugbosi M; Spigelman M;
N Engl J Med; 2020 Mar; 382(10):893-902. PubMed ID: 32130813
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and Pharmacodynamic Modeling Analysis of Delpazolid (LCB01-0371) in Adult Patients with Pulmonary Tuberculosis.
Lee SM; Choi SC; Mun KR; Seo JY; Cho YL; Shim TS; Lim HS
J Clin Pharmacol; 2024 Jul; 64(7):849-859. PubMed ID: 38436463
[TBL] [Abstract][Full Text] [Related]
25. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
Velayutham BV; Allaudeen IS; Sivaramakrishnan GN; Perumal V; Nair D; Chinnaiyan P; Paramasivam PK; Dhanaraj B; Santhanakrishnan RK; Navaneethapandian GP; Marimuthu MK; Kumar V; Kandasamy C; Dharuman K; Elangovan T; Narasimhan M; Rathinam S; Vadivelu G; Rathinam P; Chockalingam C; Jayabal L; Swaminathan S; Shaheed JM
Clin Infect Dis; 2014 Nov; 59(10):e142-9. PubMed ID: 25028463
[TBL] [Abstract][Full Text] [Related]
26. Increasing pathomorphism of pulmonary tuberculosis: an observational study of slow clinical, microbiological and imaging response of lung tuberculosis to specific treatment. Which role for linezolid?
Manfredi R; Nanetti A; Dal Monte P; Calza L
Braz J Infect Dis; 2009 Aug; 13(4):297-303. PubMed ID: 20231995
[TBL] [Abstract][Full Text] [Related]
27. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.
Dietze R; Hadad DJ; McGee B; Molino LP; Maciel EL; Peloquin CA; Johnson DF; Debanne SM; Eisenach K; Boom WH; Palaci M; Johnson JL
Am J Respir Crit Care Med; 2008 Dec; 178(11):1180-5. PubMed ID: 18787216
[TBL] [Abstract][Full Text] [Related]
28. Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial.
Kwak N; Jeon D; Park Y; Kang YA; Kim KJ; Kim YR; Kwon BS; Kwon YS; Kim HJ; Lee JH; Lee JY; Lee JK; Mok J; Cheon M; Park J; Hahn S; Yim JJ
Trials; 2022 Aug; 23(1):666. PubMed ID: 35978342
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial.
Padmapriyadarsini C; Bhavani PK; Natrajan M; Ponnuraja C; Kumar H; Gomathy SN; Guleria R; Jawahar SM; Singh M; Balganesh T; Swaminathan S
BMJ Open; 2019 Mar; 9(3):e024363. PubMed ID: 30826761
[TBL] [Abstract][Full Text] [Related]
30. Pretomanid for tuberculosis: a systematic review.
Gils T; Lynen L; de Jong BC; Van Deun A; Decroo T
Clin Microbiol Infect; 2022 Jan; 28(1):31-42. PubMed ID: 34400340
[TBL] [Abstract][Full Text] [Related]
31. Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
Jawahar MS; Banurekha VV; Paramasivan CN; Rahman F; Ramachandran R; Venkatesan P; Balasubramanian R; Selvakumar N; Ponnuraja C; Iliayas AS; Gangadevi NP; Raman B; Baskaran D; Kumar SR; Kumar MM; Mohan V; Ganapathy S; Kumar V; Shanmugam G; Charles N; Sakthivel MR; Jagannath K; Chandrasekar C; Parthasarathy RT; Narayanan PR
PLoS One; 2013; 8(7):e67030. PubMed ID: 23843980
[TBL] [Abstract][Full Text] [Related]
32. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Solodovnikova V; Liverko I; Moodliar R; Dodd M; Ngubane N; Rassool M; McHugh TD; Spigelman M; Moore DAJ; Ritmeijer K; du Cros P; Fielding K;
N Engl J Med; 2022 Dec; 387(25):2331-2343. PubMed ID: 36546625
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
[TBL] [Abstract][Full Text] [Related]
34. [Present and future in the use of anti-tubercular drugs].
Didilescu C; Craiova UM
Pneumologia; 2011; 60(4):198-201. PubMed ID: 22420168
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
Korotych O; Achar J; Gurbanova E; Hovhannesyan A; Lomtadze N; Ciobanu A; Skrahina A; Dravniece G; Kuksa L; Rich M; Khachatryan N; Germanovych M; Kadyrov A; Terleieva I; Akhundova I; Adenov M; Durdyeva M; Kiria N; Parpieva N; Yatskevich N; Jumayev R; Nurov R; Diktanas S; Vilc V; Migliori GB; Yedilbayev A
Lancet Infect Dis; 2024 Jun; ():. PubMed ID: 38880112
[TBL] [Abstract][Full Text] [Related]
36. New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?
Chen RH; Burke A; Cho JG; Alffenaar JW; Davies Forsman L
Pharmaceutics; 2024 Jun; 16(6):. PubMed ID: 38931939
[TBL] [Abstract][Full Text] [Related]
37. Linezolid for treatment of chronic extensively drug-resistant tuberculosis.
Lee M; Lee J; Carroll MW; Choi H; Min S; Song T; Via LE; Goldfeder LC; Kang E; Jin B; Park H; Kwak H; Kim H; Jeon HS; Jeong I; Joh JS; Chen RY; Olivier KN; Shaw PA; Follmann D; Song SD; Lee JK; Lee D; Kim CT; Dartois V; Park SK; Cho SN; Barry CE
N Engl J Med; 2012 Oct; 367(16):1508-18. PubMed ID: 23075177
[TBL] [Abstract][Full Text] [Related]
38. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.
Dorman SE; Johnson JL; Goldberg S; Muzanye G; Padayatchi N; Bozeman L; Heilig CM; Bernardo J; Choudhri S; Grosset JH; Guy E; Guyadeen P; Leus MC; Maltas G; Menzies D; Nuermberger EL; Villarino M; Vernon A; Chaisson RE;
Am J Respir Crit Care Med; 2009 Aug; 180(3):273-80. PubMed ID: 19406981
[TBL] [Abstract][Full Text] [Related]
39. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
40. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
